Intratumoral injection of norcantharidin liposome emulsion hybrid delivery system amplifies the cancer-fighting effects of oral sorafenib against hepatocellular carcinoma.

[1]  E. Yousef,et al.  Norcantharidin potentiates sorafenib antitumor activity in hepatocellular carcinoma rat model through inhibiting IL-6/STAT3 pathway. , 2023, Translational research : the journal of laboratory and clinical medicine.

[2]  Jia Hua Cheng,et al.  Review targeted drug delivery systems for norcantharidin in cancer therapy , 2022, Journal of Nanobiotechnology.

[3]  Xing Tang,et al.  Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF-κB pathway. , 2022, International journal of pharmaceutics.

[4]  C. Yuan,et al.  Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy , 2022, Frontiers in Immunology.

[5]  Yong-guang Yang,et al.  Application of systemic treatment in conversion therapy options for liver cancer , 2022, Frontiers in Oncology.

[6]  T. Meyer,et al.  Hepatocellular carcinoma , 2022, The Lancet.

[7]  Yongbo Peng,et al.  Norcantharidin promotes cancer radiosensitization through Cullin1 neddylation‐mediated CDC6 protein degradation , 2022, Molecular carcinogenesis.

[8]  Jiamin Cheng,et al.  Efficacy and safety in advanced hepatocellular carcinoma using atezolizumab plus bevacizumab combined with interventional therapy: A retrospective analysis of real-world evidence. , 2022, Journal of Clinical Oncology.

[9]  Xinyi Tan,et al.  Preclinical evaluations of Norcantharidin liposome and emulsion hybrid delivery system with improved encapsulation efficiency and enhanced antitumor activity , 2022, Expert opinion on drug delivery.

[10]  Jinlong Li,et al.  Norcantharidin Induces Immunogenic Cell Death of Bladder Cancer Cells through Promoting Autophagy in Acidic Culture , 2022, International journal of molecular sciences.

[11]  Huachuan Zheng,et al.  Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook , 2022, Journal of hepatocellular carcinoma.

[12]  B. Zhai,et al.  Correction to: LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells , 2021, Journal of Experimental & Clinical Cancer Research.

[13]  M. Robson,et al.  496 Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients , 2021, Journal for ImmunoTherapy of Cancer.

[14]  Zhixing He,et al.  Norcantharidin ameliorates the development of murine lupus via inhibiting the generation of IL-17 producing cells , 2021, Acta Pharmacologica Sinica.

[15]  N. Latt,et al.  Expanding indications for liver transplantation in the era of liver transplant oncology , 2021, World journal of gastrointestinal surgery.

[16]  Tiantian Wang,et al.  Norcantharidin-blocked ANXA2P2 inhibits fibroblast proliferation by increasing UBAP2L mRNA stability through LIN28B. , 2021, Life sciences.

[17]  A. Cervantes,et al.  Hepatocellular carcinoma , 2021, Nature Reviews Disease Primers.

[18]  Jun Fang,et al.  Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. , 2020, Advanced drug delivery reviews.

[19]  Zhonglin Han,et al.  Inhibition of RAGE by FPS-ZM1 alleviates renal injury in spontaneously hypertensive rats. , 2020, European journal of pharmacology.

[20]  Y. Jaillais,et al.  Phospholipids across scales: lipid patterns and plant development. , 2020, Current opinion in plant biology.

[21]  Wen Chen,et al.  Comprehensive managements of metastatic renal tumor with Mayo III inferior vena cava tumor thrombus: a case report , 2020, Translational andrology and urology.

[22]  Yuliang Zhao,et al.  Ultrasmall BiOI Quantum Dots with Efficient Renal Clearance for Enhanced Radiotherapy of Cancer , 2020, Advanced science.

[23]  Sung-Dae Cho,et al.  Contribution of p38 MAPK Pathway to Norcantharidin-Induced Programmed Cell Death in Human Oral Squamous Cell Carcinoma , 2019, International journal of molecular sciences.

[24]  Qiang He,et al.  Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer. , 2019, Cancer letters.

[25]  Xiaochun Li,et al.  Norcantharidin inhibits proliferation and promotes apoptosis via c‐Met/Akt/mTOR pathway in human osteosarcoma cells , 2019, Cancer science.

[26]  Jun Xia,et al.  Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[27]  Jiachao Zhang,et al.  Consumption of Goats’ Milk Protects Mice From Carbon Tetrachloride-Induced Acute Hepatic Injury and Improves the Associated Gut Microbiota Imbalance , 2018, Front. Immunol..

[28]  Jinhua Huang,et al.  The history of interventional therapy for liver cancer in China , 2018, Journal of interventional medicine.

[29]  A. Bosserhoff,et al.  Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance , 2017, Gut.

[30]  Xiao-Feng Li,et al.  Norcantharidin alone or in combination with crizotinib induces autophagic cell death in hepatocellular carcinoma by repressing c-Met-mTOR signaling , 2017, Oncotarget.

[31]  F. Angenstein,et al.  Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells. , 2017, European journal of cancer.

[32]  Zeping Han,et al.  Norcantharidin Inhibits SK-N-SH Neuroblastoma Cell Growth by Induction of Autophagy and Apoptosis , 2017, Technology in cancer research & treatment.

[33]  S. Eguchi,et al.  Liver transplantation in Japan , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[34]  E. Chiorean,et al.  Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma , 2016, The oncologist.

[35]  Gang Li,et al.  Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms. , 2016, World journal of gastroenterology.

[36]  S. Dooley,et al.  PI3K/AKT/mTOR‐dependent stabilization of oncogenic far‐upstream element binding proteins in hepatocellular carcinoma cells , 2016, Hepatology.

[37]  F. Batteux,et al.  Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis , 2015, Reproductive Sciences.

[38]  Jian-qing Wang,et al.  [Effect of Norcantharidin on Hematopoietic Function in Leucopenia Model Rat Induced by Cyclophosphamide]. , 2015, Zhongguo shi yan xue ye xue za zhi.

[39]  Cuifang Cai,et al.  A highly stable norcantharidin loaded lipid microspheres: preparation, biodistribution and targeting evaluation. , 2014, International journal of pharmaceutics.

[40]  Xuehao Wang,et al.  Cantharidin Exerts Anti-Hepatocellular Carcinoma by Mir-214 Modulating Macrophage Polarization , 2014, International journal of biological sciences.

[41]  C. Bartolozzi,et al.  Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma , 2012, Cancer Chemotherapy and Pharmacology.

[42]  Yue Fan,et al.  Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. , 2011, International journal of oncology.

[43]  L. Deng,et al.  Norcantharidin analogues: a patent review (2006 – 2010) , 2011, Expert opinion on therapeutic patents.

[44]  R. Finn,et al.  Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2011, Clinical Cancer Research.

[45]  P. Galle,et al.  Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment , 2010, Oncology.

[46]  P. Schirmacher,et al.  Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells , 2009, Hepatology.

[47]  Defen Zhang,et al.  Survival analysis of sorafenib combined with TACE in hepatocellular carcinoma patients , 2020 .

[48]  Xiao-yan Tang,et al.  The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture , 2010, Molecular Biology Reports.